Jean Abraham

6.2k total citations
40 papers, 896 citations indexed

About

Jean Abraham is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Jean Abraham has authored 40 papers receiving a total of 896 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 20 papers in Cancer Research and 10 papers in Genetics. Recurrent topics in Jean Abraham's work include Breast Cancer Treatment Studies (15 papers), Cancer Treatment and Pharmacology (9 papers) and HER2/EGFR in Cancer Research (9 papers). Jean Abraham is often cited by papers focused on Breast Cancer Treatment Studies (15 papers), Cancer Treatment and Pharmacology (9 papers) and HER2/EGFR in Cancer Research (9 papers). Jean Abraham collaborates with scholars based in United Kingdom, Canada and Australia. Jean Abraham's co-authors include Helena Earl, Carlos Caldas, Paul D.P. Pharoah, Janet Dunn, Louise Hiller, Alison M. Dunning, Susan Ingle, Anne-Laure Vallier, Ellen Copson and Craig Luccarini and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Jean Abraham

38 papers receiving 879 citations

Peers

Countries citing papers authored by Jean Abraham

Since Specialization

Citations

This map shows the geographic impact of Jean Abraham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean Abraham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean Abraham more than expected).

Fields of papers citing papers by Jean Abraham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean Abraham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean Abraham. The network helps show where Jean Abraham may publish in the future.

Co-authorship network of co-authors of Jean Abraham

This figure shows the co-authorship network connecting the top 25 collaborators of Jean Abraham. A scholar is included among the top collaborators of Jean Abraham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean Abraham. Jean Abraham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data 2025 ·PubMed ·Helena Earl, Louise Hiller, Janet Dunn, (unknown), Pierfranco Conté, Roberto D’Amico, Valentina Guarneri, Heikki Joensuu, Teppo Huttunen, Dora Hatzidaki, Vassilis Georgoulias, Jean Abraham, David Miles, David Cameron, Andrew Wardley, Xavier Pivot	0
2	Mainstreaming of genomics in oncology: a nationwide survey of the genomics training needs of UK oncologists 2023 ·Clinical Medicine ·(unknown), (unknown), Jean Abraham, Katie Snape, Katrina Tatton‐Brown, Zoe Kemp, Ellen Copson, Mark R. Openshaw	11
3	NRG1 fusions in breast cancer 2021 ·Breast Cancer Research ·Karen Howarth, (unknown), Susanna L. Cooke, Suet‐Feung Chin, Jessica C. Pole, Ernest Turro, Matthew Eldridge, (unknown), Oscar M. Rueda, Chris Boursnell, Jean Abraham, Carlos Caldas, Paul A. Edwards	17
4	Fbxl17 is rearranged in breast cancer and loss of its activity leads to increased global O-GlcNAcylation 2019 ·Cellular and Molecular Life Sciences ·(unknown), (unknown), Felipe R. Teixeira, (unknown), Oscar M. Rueda, Jean Abraham, Carlos Caldas, Paul A. Edwards, Heike Laman	8
5	Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial 2017 ·Annals of Oncology ·Hager R. Ali, A. Dariush, Jeremy Thomas, Elena Provenzano, Janet Dunn, Louise Hiller, (unknown), Jean Abraham, Tammy Piper, JMS Bartlett, David Cameron, Larry Hayward, (unknown), Paul D.P. Pharoah, M. J. Irwin, N. A. Walton, Helena Earl, Carlos Caldas	31
6	Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial 2017 ·Annals of Oncology ·Helena Earl, Louise Hiller, Janet Dunn, (unknown), (unknown), (unknown), Ioannis Gounaris, Jean Abraham, Luke Hughes‐Davies, Karen McAdam, Stephen Chan, (unknown), Tamas Hickish, Daniel Rea, Carlos Caldas, John M.S. Bartlett, David Cameron, Elena Provenzano, Jeremy Thomas, Richard L. Hayward	28
7	The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study 2016 ·PLoS ONE ·Leila Dorling, Siddhartha Kar, Kyriaki Michailidou, Louise Hiller, Anne-Laure Vallier, Susan Ingle, (unknown), S. Bowden, Janet Dunn, Chris Twelves, Christopher Poole, Carlos Caldas, Helena Earl, (unknown), Jean Abraham	8
8	Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer 2016 ·Breast Cancer Research ·H. Raza Ali, Aliakbar Dariush, Elena Provenzano, Helen Bardwell, Jean Abraham, Mahesh Iddawela, Anne-Laure Vallier, Louise Hiller, Janet Dunn, S. Bowden, Tamas Hickish, Karen McAdam, Stephen Houston, M. J. Irwin, Paul D.P. Pharoah, James D. Brenton, N. A. Walton, Helena Earl, Carlos Caldas	64
9	Understanding of BRCA VUS genetic results by breast cancer specialists 2015 ·BMC Cancer ·(unknown), Ellen Copson, Tom Maishman, Jean Abraham, Diana Eccles	85
10	Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer 2015 ·International Journal of Gynecological Cancer ·Karen Sayal, Ioannis Gounaris, Bristi Basu, (unknown), (unknown), Karen Hosking, Mahesh Iddawela, Mercedes Jimenez‐Liñan, Jean Abraham, James D. Brenton, Helen Hatcher, Helena Earl, Christine Parkinson	12
11	Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes – what does it all mean? 2015 ·BMC Medicine ·Helena Earl, Elena Provenzano, Jean Abraham, Janet Dunn, Anne-Laure Vallier, Ioannis Gounaris, Louise Hiller	44
12	A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities 2015 ·BMC Medicine ·Jean Abraham, Louise Hiller, Leila Dorling, Anne-Laure Vallier, Janet Dunn, S. Bowden, Susan Ingle, Linda Jones, (unknown), Christopher Twelves, Christopher Poole, Paul D.P. Pharoah, Carlos Caldas, Helena Earl	25
13	A Bayesian adaptive design for biomarker trials with linked treatments 2015 ·British Journal of Cancer ·James Wason, Jean Abraham, Richard D. Baird, (unknown), Anne-Laure Vallier, James D. Brenton, Helena Earl, Adrian Mander	22
14	Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel 2014 ·Clinical Cancer Research ·Jean Abraham, Qi Guo, Leila Dorling, Jonathan P. Tyrer, Susan Ingle, (unknown), Anne-Laure Vallier, Louise Hiller, Stephen R. Russell, Linda Jones, S. Bowden, Janet Dunn, Christopher Poole, Carlos Caldas, Paul D.P. Pharoah, Helena Earl	82
15	The impact of center accreditation on hematopoietic cell transplantation (HCT) 2014 ·Bone Marrow Transplantation ·Schelomo Marmor, James W. Begun, Jean Abraham, Beth A Virnig	14
16	Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial 2013 ·International Journal of Cancer ·Alaa M. Ali, Elena Provenzano, John M.S. Bartlett, Jean Abraham, Kristy Driver, Alison F. Munro, Christopher Twelves, Christopher Poole, Louise Hiller, Janet Dunn, Helena Earl, Carlos Caldas, Paul D.P. Pharoah	13
17	A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial 2013 ·British Journal of Cancer ·Elena Provenzano, (unknown), (unknown), (unknown), S. Bowden, Alex Grier, Nicola Fenwick, Jean Abraham, Mahesh Iddawela, Carlos Caldas, Louise Hiller, Janet Dunn, Helena Earl	23
18	Neo-tAnGo science: A translational study of PAM 50 sub-typing in sequential fresh tissue samples during neoadjuvant chemotherapy. 2013 ·Journal of Clinical Oncology ·Helena Earl, Suet‐Feung Chin, Mark Dunning, Mahesh Iddawela, Oscar M. Rueda, Roslin Russell, Linda Jones, (unknown), Luke Hughes‐Davies, Jean Abraham, Stephen Chan, Anthony Skene, Kim Benstead, Christopher Gallagher, Nicholas Murray, Diana Ritchie, Janet Dunn, Louise Hiller, Elena Provenzano, Carlos Caldas, (unknown)	1
19	Saliva samples are a viable alternative to blood samples as a source of DNA for high throughput genotyping 2012 ·BMC Medical Genomics ·Jean Abraham, Mel Maranian, Inmaculada Spiteri, Roslin Russell, Susan Ingle, Craig Luccarini, Helena Earl, Paul D.P. Pharoah, Alison M. Dunning, Carlos Caldas	120
20	Common Polymorphisms in the Prostaglandin Pathway Genes and Their Association with Breast Cancer Susceptibility and Survival 2009 ·Clinical Cancer Research ·Jean Abraham, Patricia Harrington, Kristy Driver, Jonathan P. Tyrer, Douglas F. Easton, Alison M. Dunning, Paul D.P. Pharoah	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact